Back to results
US 12,668,774 B2Granted
Product, system and method of cell cultivation
AssigneeBTL Healthcare Technologies A.S.
InventorsJiri Janousek, Marek Sirl, Peter Gorilak, Matej Kubovcak
Life of this patent
Estimating the term…
Abstract
The present invention provides products, systems, and methods of cultivation of non-human metazoan cells.
Claims30
A genetically modified non-human metazoan cell line comprising:
- a. a gene encoding modified telomerase reverse transcriptase (TERT) or an allelic variant thereof resulting in cell immortalization, wherein the TERT gene is located at a safe harbor site within the genome of the cell;
- and
- b. a genetic modification that alters the level of expression of at least one gene selected from genes encoding fibroblast growth factor (FGF) molecules, resulting in reduced growth factor requirements for the cultivation of non-human metazoan cells compared to wild-type cell lines, wherein the FGF molecule is regulated by a promoter;
- and
- c. adaptation of the cell line to grow in a culture medium comprising a protein hydrolysate at a concentration, expressed as dry protein weight, in a range from 8 g/L to 50 g/L.
2 more elements
A genetically modified non-human metazoan cell line comprising:
- a. a gene encoding modified telomerase reverse transcriptase (TERT) or an allelic variant thereof, wherein the TERT gene is located at a safe harbor site within the genome of the cell;
- and
- b. adaptation of the cell line to grow in a culture medium comprising protein hydrolysate as a main source of amino acids, wherein the total input of supplemental amino acids added separately to the culture medium comprising the protein hydrolysate is in the range of 0.2% to 25%.
A food product composition comprising genetically modified non-human metazoan cells, wherein the genetically modified non-human metazoan cells comprise:
- a. a gene encoding modified telomerase reverse transcriptase (TERT) or an allelic variant thereof resulting in cell immortalization wherein the TERT gene is located at a safe harbor site within the genome of the cell;
- and
- b. adaptation of the cell line to grow in a culture medium comprising protein hydrolysate as a main source of amino acids, wherein at least 75% by weight of the total amino acid input in the culture medium is derived from the protein hydrolysate.
Dependencies are inferred from the claim text.